158 related articles for article (PubMed ID: 8289991)
1. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.
Arnadottir M; Eriksson LO; Thysell H; Karkas JD
Nephron; 1993; 65(3):410-3. PubMed ID: 8289991
[TBL] [Abstract][Full Text] [Related]
2. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.
Arnadottir M; Eriksson LO; Germershausen JI; Thysell H
Nephron; 1994; 68(1):57-62. PubMed ID: 7991041
[TBL] [Abstract][Full Text] [Related]
3. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.
Cheng H; Rogers JD; Sweany AE; Dobrinska MR; Stein EA; Tate AC; Amin RD; Quan H
Pharm Res; 1992 Dec; 9(12):1629-33. PubMed ID: 1488408
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.
Kusus M; Stapleton DD; Lertora JJ; Simon EE; Dreisbach AW
Am J Med Sci; 2000 Dec; 320(6):394-7. PubMed ID: 11149552
[TBL] [Abstract][Full Text] [Related]
5. [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].
Meier C; Stey C; Brack T; Maggiorini M; Risti B; Krähenbühl S
Schweiz Med Wochenschr; 1995 Jul; 125(27-28):1342-6. PubMed ID: 7624744
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
7. [Rhabdomyolysis caused by simvastatinin a patient following heart transplantation and cyclosporine therapy].
Blaison G; Weber JC; Sachs D; Korganow AS; Martin T; Kretz JG; Pasquali JL
Rev Med Interne; 1992; 13(1):61-3. PubMed ID: 1410877
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Cheng H; Sutton SC; Pipkin JD; Zentner GM; Rogers JD; Schwartz JI; Mitchel YB; Grasing K; Schwartz MS; Amin RD
Pharm Res; 1993 Nov; 10(11):1683-7. PubMed ID: 8290485
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
10. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors.
Ballarè M; Campanini M; Airoldi G; Zaccala G; Bertoncelli MC; Cornaglia G; Porzio M; Monteverde A
Minerva Gastroenterol Dietol; 1992; 38(1):41-4. PubMed ID: 1520752
[TBL] [Abstract][Full Text] [Related]
12. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
14. Drug-interaction-induced rhabdomyolysis.
Segaert MF; De Soete C; Vandewiele I; Verbanck J
Nephrol Dial Transplant; 1996 Sep; 11(9):1846-7. PubMed ID: 8918636
[No Abstract] [Full Text] [Related]
15. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
[TBL] [Abstract][Full Text] [Related]
16. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
[TBL] [Abstract][Full Text] [Related]
17. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.
Wanner C; Lubrich-Birkner I; Summ O; Wieland H; Schollmeyer P
Nephron; 1992; 62(1):40-6. PubMed ID: 1436290
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical tolerance of lovastatin and simvastatin.
Bilheimer DW
Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
20. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine.
Vlahakos DV; Manginas A; Chilidou D; Zamanika C; Alivizatos PA
Transplantation; 2002 Jun; 73(12):1962-4. PubMed ID: 12131698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
